In the Claims:

1. (Cancelled)

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Withdrawn) DNA sequence encoding an adjuvant comprising at least the fragment of the P40 protein Klebsiella pneumoniae, said fragment having the amino acid sequence of SEQ ID No: 8.

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Withdrawn) A pharmaceutical composition comprising said DNA sequence of claim 7, and a pharmaceutically acceptable carrier.

17. (Withdrawn) A vaccine for intramuscular or intradermal administration comprising said DNA sequence of claim 7.

18. (Cancelled)

19. (Currently Amended) A ~~Process~~ process for increasing the immunogenicity of an antigen or a hapten, characterized in that the said process comprises the step of attaching the antigen or the hapten ~~is attached~~ to an adjuvant to form an immunogenic complex, said adjuvant comprising ~~the~~ a fragment having the sequence ~~127 to 179 (~~SEQ ID No. 8~~)~~ of the P40 protein of *Klebsiella* ~~K.~~ ~~pneumoniae~~ *pneumoniae* having the sequence SEQ ID No. 2.

20. (Currently Amended) The ~~Process~~ process according to claim 19, characterized in that said adjuvant is ~~the~~ a fragment having the sequence ~~108 to 179 (~~SEQ ID No. 6~~)~~ of the P40 protein of ~~K. pneumoniae having the sequence ID No. 2~~ *Klebsiella pneumoniae*.

21. (Currently Amended) The ~~Process~~ process according to claim 19, characterized in that said adjuvant is ~~the~~ a fragment having the sequence ~~1 to 179 (~~SEQ ID No. 4~~)~~ of the P40 protein of ~~K. pneumoniae having the sequence ID No. 2~~ *Klebsiella pneumoniae*.

22. (Currently Amended) The ~~Process~~ process according to claim 19, characterized in that said adjuvant is the P40 protein of ~~K. pneumoniae~~ *Klebsiella pneumoniae* having the sequence ID No. 2.

23. (Cancelled)

24. (Currently Amended) The ~~Process~~ process according to claim 19, characterized in that said antigen or ~~a~~ the hapten consists of ~~a~~ an immunogenic fragment of the G protein of the respiratory syncytial virus (RSV).

25. (Currently Amended) The ~~Process~~ process according to claim 19, characterized in that said antigen or the ~~a~~ hapten is attached to the adjuvant by a covalent bond.

26. (Currently Amended) The ~~Process~~ process according to claim 19, characterized in that said antigen or the hapten is attached to the adjuvant by chemical coupling.

27. (Currently Amended) The ~~Process~~ process according to claim 19, characterized in that said antigen or the hapten is fused to the adjuvant by genetic manipulation.

28. (Currently Amended) The ~~Process~~ process according to claim 19, characterized in that said antigen or the ~~a~~ hapten which is attached to the adjuvant, is fused to a protein which is a receptor for a serum protein.

29. (Currently Amended) The ~~Process~~ process according to claim 19, characterized in that said antigen or the ~~a~~ hapten which is attached to the adjuvant, is fused to a protein which is a receptor for the human serum albumin.